Semaglutide

Key Research Papers and Clinical Trials

Current semaglutide research encompasses several areas beyond its established use in diabetes and weight management, though evidence remains limited in many emerging applications.

Real-World Evidence Studies

A Danish community pharmacy-based cross-sectional survey examined treatment patterns and experienced effects of semaglutide for weight management among adult users, providing insights into real-world usage patterns. Additionally, a comparative effectiveness study using target trial emulation methodology investigated GLP-1 receptor agonists versus oral agents for insulin discontinuation in type 2 diabetes patients, though specific sample sizes and detailed results are not available from the current evidence.

Mechanistic and Safety Research

The CRAVE study investigated changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy, offering insights into the broader metabolic effects of these medications. A pharmacovigilance study analyzed the FAERS database to assess the safety profile of tirzepatide (a related GLP-1 receptor agonist) in real-world clinical practice.

Clinical Trial Development

Several Phase 1 trials have been completed or are in development:

• A completed bioavailability study (NCT05784402) compared semaglutide blood levels across different oral tablet formulations in healthy participants
• A completed Phase 1 study (NCT05435677) examined how insulin icodec and semaglutide work in Chinese patients with type 2 diabetes when given alone or together
• A terminated Phase 1 trial (NCT05671653) was investigating drug interactions between experimental GLP-1 drugs and common medications including birth control pills

Emerging Applications

Research is exploring semaglutide's potential in new therapeutic areas, including a Phase 2 study for Alzheimer's disease treatment and monitoring (NCT07135245), though this trial is not yet recruiting. A Phase 1 study examining semaglutide for polycystic ovarian syndrome was withdrawn (NCT06222437).

The evidence base remains limited for many of these emerging applications, with most studies still in early phases or providing only preliminary real-world data without detailed outcomes reporting.